Journal
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS
Volume 13, Issue 8, Pages 1432-1439Publisher
BENTHAM SCIENCE PUBL
DOI: 10.2174/1871527313666141023141545
Keywords
Acetylcholinesterase; Alzheimer's disease; butyrylcholinesterase; cholinergic deficit; cholinesterase inhibitors; type 2 diabetes mellitus
Categories
Funding
- NATIONAL INSTITUTE ON AGING [ZIAAG000311] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z99 AG999999] Funding Source: Medline
Ask authors/readers for more resources
Both Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of beta-amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Altered levels of AChE and BuChE both in AD as well as in T2DM imply that those two enzymes may be playing a pivotal role in the pathogenesis of the two disorders. AD and T2DM are both characterized by elevated levels of AChE and BuChE in the plasma. On the other hand, in AD the brain levels of AChE go down while those of BuChE go up, resulting in deregulation in balance between AChE and BuChE. This imbalance and change in the AChE/BuChE ratio causes cholinergic deficit in the brain, i.e. deficiency in the brain neurotransmitter acetylcholine. With better understanding of the inter-relationship of AChE and BuChE levels in normality as well as abnormality, AD and T2DM can be effectively treated. Thus, general cholinesterase inhibitors that inhibit both AChE and BuChE as well as highly selective BuChE inhibitors may have potential therapeutic benefits in the treatment of AD and other related dementias.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available